PMID- 33630272
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210525
IS  - 2198-6576 (Print)
IS  - 2198-6584 (Electronic)
IS  - 2198-6576 (Linking)
VI  - 8
IP  - 1
DP  - 2021 Mar
TI  - Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from 
      the US-Based Corrona Rheumatoid Arthritis Registry.
PG  - 467-481
LID - 10.1007/s40744-021-00285-0 [doi]
AB  - INTRODUCTION: Understanding the durability of response to treatment and factors 
      associated with failure to maintain response in a real-world setting can inform 
      treatment decisions for patients with rheumatoid arthritis (RA). The aim of this 
      study was to analyze durability of response to tocilizumab (TCZ) and factors 
      associated with durability among US patients with RA in routine clinical 
      practice. METHODS: TCZ initiators in the Corrona RA Registry were included. 
      Durability of response was defined as maintaining continuous TCZ treatment and 
      either an improvement of at least minimum clinically important difference (MCID) 
      in Clinical Disease Activity Index (CDAI) score or low disease activity (LDA). 
      Secondary analyses included patients treated with intravenous (IV) TCZ and 
      excluded those who discontinued TCZ without reporting reasons for 
      discontinuation. Durability was calculated with Kaplan-Meier survival analysis. 
      Cox proportional hazards modeling identified factors associated with durability. 
      RESULTS: Among 1789 TCZ initiators, 466, 272, and 162 were persistent (with or 
      without durable response) with follow-up visits at 1, 2, and 3 years, 
      respectively. Median MCID durability of response in CDAI was > 50% after 
      36 months overall, 26 months for TCZ-IV, and > 50% after 36 months for those with 
      known reasons for discontinuation; longer durability was associated with 
      increased duration of RA and higher baseline CDAI score and shorter durability 
      with history of malignancy and history of diabetes. Median LDA durability of 
      response was 13.0 months overall, for TCZ-IV, and for those with known reasons 
      for discontinuation; shorter durability was associated with history of 
      malignancy, history of diabetes, and higher baseline CDAI score. CONCLUSIONS: 
      Median durability of response to TCZ in RA was > 3 years when defined as 
      maintenance of MCID in CDAI score and > 1 year with the more stringent criteria 
      of maintenance of LDA. TRIAL REGISTRATION: ClinicalTrials.gov identifier, 
      NCT01402661.
FAU - Pappas, Dimitrios A
AU  - Pappas DA
AD  - Corrona, LLC, Waltham, MA, USA. dpappas@corrona.org.
FAU - Blachley, Taylor
AU  - Blachley T
AD  - Corrona, LLC, Waltham, MA, USA.
FAU - Best, Jennie H
AU  - Best JH
AD  - Genentech, Inc., South San Francisco, CA, USA.
FAU - Zlotnick, Steve
AU  - Zlotnick S
AD  - Genentech, Inc., South San Francisco, CA, USA.
FAU - Reiss, William G
AU  - Reiss WG
AD  - Genentech, Inc., South San Francisco, CA, USA.
FAU - Emeanuru, Kelechi
AU  - Emeanuru K
AD  - Corrona, LLC, Waltham, MA, USA.
FAU - Kremer, Joel M
AU  - Kremer JM
AD  - Corrona, LLC, Waltham, MA, USA.
AD  - Albany Medical College and the Center for Rheumatology, Albany, NY, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01402661
PT  - Journal Article
DEP - 20210225
PL  - England
TA  - Rheumatol Ther
JT  - Rheumatology and therapy
JID - 101674543
PMC - PMC7991054
OTO - NOTNLM
OT  - Biological therapies
OT  - Biologics
OT  - Durability of response
OT  - Real-world data
OT  - Rheumatoid arthritis
OT  - Tocilizumab
EDAT- 2021/02/26 06:00
MHDA- 2021/02/26 06:01
PMCR- 2021/02/25
CRDT- 2021/02/25 12:17
PHST- 2020/11/25 00:00 [received]
PHST- 2021/01/23 00:00 [accepted]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/02/26 06:01 [medline]
PHST- 2021/02/25 12:17 [entrez]
PHST- 2021/02/25 00:00 [pmc-release]
AID - 10.1007/s40744-021-00285-0 [pii]
AID - 285 [pii]
AID - 10.1007/s40744-021-00285-0 [doi]
PST - ppublish
SO  - Rheumatol Ther. 2021 Mar;8(1):467-481. doi: 10.1007/s40744-021-00285-0. Epub 2021 
      Feb 25.